Tobacco Stocks See Renewed Interest from Investors
Wall Street investors are shifting focus back to tobacco stocks, overshadowing years of ethical concerns, as the industry’s strong move towards smoke-free alternatives complicates traditional moral judgments.
For nearly ten years, many pension funds and large endowments had blacklisted tobacco companies, operating under strict guidelines.
However, that ban appears to be lifting. Major tobacco firms are now experiencing significant revenues from non-combustible products and are “rejoining polite society,” which has led to improved stock market evaluations thanks to a resurgence of institutional investment, as reported.
This trend gained traction recently when the FDA authorized Philip Morris to market 20 Zyn nicotine pouches as a safer option compared to regular smoking. The decision, made on June 30, indicated that non-tobacco pouches could lower the risk of serious health issues like lung cancer and heart disease.
This announcement came shortly after New York Governor Kathy Hochul implemented a hefty 75% wholesale tax on alternative tobacco products, nicknamed the “bro tax.”
The FDA’s ruling prompted swift reactions from major investment banks. Morgan Stanley has since increased its price target for Philip Morris to $200, reflecting optimism about Zyn Ultra’s prospects.
“This development further increases our confidence,” noted Morgan Stanley analysts, indicating a $250 bull case scenario is now more plausible since smoke-free products are becoming a major revenue source for Philip Morris.
Bank of America echoed this support, raising its target to $209, citing a successful smokeless strategy.
Currently, Philip Morris earns approximately 41% of its income from non-combustible products and enjoys a notable 70% price premium over competitors that still heavily depend on traditional cigarette sales.
Meanwhile, British American Tobacco (BAT), known for Lucky Strike and Vuse e-cigarettes, is undergoing significant changes to enhance its competitive edge. The company plans to reduce its workforce by 9,000 globally, outsourcing roles to a consulting firm and leveraging AI for efficiency. These cuts aim to save around $800 million yearly by 2028, allowing more resources for smokeless product development.
“The scale of the job cuts is unexpected,” remarked Barclays analyst Paralav Mittal.
Despite the restructuring, analysts maintain a positive outlook. Jefferies and UBS recently reinforced their Buy ratings on BAT, joining a majority of Wall Street experts who feel optimistic about the company’s prospects as it aims to capture a larger share of the U.S. oral nicotine market.
As sales of combustible cigarettes decline over the years, the rapid changes in the tobacco industry seem to be reshaping the landscape for institutional investors.
A recent note from Morgan Stanley concluded that “FDA approval for Zyn…is very positive” for the industry’s growth. They stated that this regulatory affirmation legitimizes the potential for harm reduction and boosts confidence in accelerating smoke-free growth.
